Daniel Dante Yeh

Background Despite parenteral nutrition (PN) being life sustaining, one of the risk factors associated with its long‐term use is intestinal failure–associated liver disease (IFALD), which increases the risk for morbidity and mortality. This review examines some of the risk factors associated with IFALD. Methods A literature review using the databases PubMed, EMBASE, and CINAHL between 2010 and 2020 was performed using search terms, including long‐term total PN and liver failure, serum plant sterols and liver failure, and complications and PN. Articles in English using both human and animal participants were included. Results The pathophysiology associated with PN and liver disease is multifactorial and influenced by the remaining small‐bowel length, presence of the ileal cecal valve, lack of enteral stimulation, type of lipid injectable emulsion (ILE), plant sterol content, and excessive calories. The type of ILE plays a major role because of the phytosterol (PS) content, affecting the microbiome composition and inhibiting key gut signals. The PS content is highest in soy oil (SO)–based ILE, which increases inflammation and impairs biliary flow. Conclusion Serum PS correlates with liver biomarker abnormalities and is highest in SO‐based ILE use compared with mixed‐oil emulsions. Selection of a low‐PS content ILE is recommended to reduce the risk of biliary cholestasis. Stimulation of the gut, if possible, is recommended to maintain gut integrity and reduce bacterial overgrowth. Fish oil (FO) shows promise in IFALD reversal however, large randomized controlled trials are needed to further establish support for the use of FO in adults.